Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 24% in early trading.
Moderna stock plunges on sales forecast cut
Moderna (MRNA) shares tumble after the pharmaceutical company lowered its sales forecast amid weak demand for COVID and RSV vaccines. Seana Smith and Brad Smith outline what investors need to know about the sales cut.
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal sales" in 2024. Analysts' concerns were heightened by the company's revised sales forecast for 2024, which projects $3 billion to $3.1 billion, falling at the low end of previous estimates.
Moderna cuts 2025 sales forecast by $1 billion on weak vaccine demand, shares fall
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19
Moderna Shares Drop to Five-Year Low After Slashing Revenue, Sales Forecasts
Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.
Moderna shares plunge as company dramatically lowers sales forecast
Axios Visuals Moderna shares plunged today to lows not seen since the early weeks of the pandemic after the company dramatically lowered its sales forecast. Zoom in: Waning demand for COVID vaccines is crushing Moderna's revenue.
Moderna Cuts 2025 Revenue Forecast by $1 Billion, Shares Drop 17% As Investors Eye $30 Support Level
Moderna shares tumbled nearly 17% on Monday after the drugmaker slashed its 2025 revenue forecast by $1 billion and announced plans to cut $1.5 billion in expenses this year. The company faces challenges balancing rising drug development costs with declining demand for Covid-19 treatments and slow adoption of its RSV medication.
Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%
Key Takeaways Moderna shares tumbled Monday after the company cut its 2025 revenue forecast by $1 billion.The company expects ...
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Analysts Issue Forecasts for Moderna FY2029 Earnings
Investment analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of Moderna in a note issued to investors on Monday, January 13th. Brookline Capital Management ...
Moderna says it’s ‘one step closer’ to a norovirus vaccine as the virus spreads across the U.S.
Stomach bug,” “cruise-ship virus,” “winter vomiting disease”—all are nicknames for norovirus, the top cause of vomiting, ...
STAT6d
Pharmalittle: We’re reading about pharma layoffs, Moderna gambling on China, and more
The number of layoffs in the U.S. pharmaceutical industry exceeded 14,000 last year, a 9% increase from 2023 ...
RBC Capital Keeps Their Hold Rating on Moderna (MRNA)
RBC Capital analyst Luca Issi maintained a Hold rating on Moderna (MRNA – Research Report) on January 13 and set a price target of $40.00. The ...
Moderna, Novavax and other vaccine names extend gains amid COVID/flu concerns
Novavax (NVAX) and other vaccine developers rise as Investors react to rising flu and COVID-19 cases in the U.S. Read more ...
Pharmaceutical Technology2d
JP Morgan 2025: Moderna stock suffers after CEO reveals conservative 2025 guidance
Moderna share price took a blow as CEO Stéphane Bancel outlined a diminished guidance for 2025. Credit: Boston Globe/ Getty Images Moderna lost more than 20% of its value on the stock market as ...
Moderna Faces Uncertainty Amidst Strategic Efforts and Competitive Challenges
J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...